For Vets

Bring us the case. Keep every clinical decision.

Refer a patient using the records already available. RosieVaccine prepares a review-ready technical package. Your clinic completes one focused review and records the clinical decision.

Veterinary review: 20 minutes

The 20 minutes covers review of the prepared RosieVaccine package. It does not include specimen collection, surgery, laboratory processing, owner consultation, administration, or waiting time.

Refer a Patient → Read the evidence →

RosieVaccine prepares the design package. Your clinic retains every clinical decision.

We prepare what your review needs. Given tumor and matched normal sequence data, our pipeline identifies cancer-specific changes, prioritizes candidate targets, and produces a traceable personalized mRNA design report for expert review. We coordinate the technical inputs; you keep the patient.

We review every referral individually — and we say no when we don't believe the science supports a reasonable design attempt.

Refer. Coordinate. Analyze. Review.

01 · REFER Refer the case Diagnosis, treatment history, timing, and whatever records exist. Partial is fine.
02 · COORDINATE We review the inputs Sample quality, sequencing feasibility, and whether a design attempt is scientifically reasonable.
03 · ANALYZE Technical design Sequencing through a qualified laboratory; our pipeline creates the traceable design.
04 · REVIEW You review the report The design report comes back to you. Every clinical decision stays yours.

Kits, prices, turnaround times, dose schedules, manufacturers, and treatment access are not promised here — those depend on capabilities and authorizations that must be current and separately approved before they appear on this page.

What your clinic provides

Diagnosis, staging, and the clinical relationship
Tumor and matched normal samples (details below)
Treatment history and records already on file
Clinical review of the design report

The samples we work from

SamplePreferredAlso workable
TumorFresh or flash-frozen at surgeryFFPE block from the pathology lab
Matched normalWhole blood, EDTA tubeBuccal swab
RecordsHistopathology reportImaging, bloodwork, surgical notes

The matched normal is what makes the design specific to that patient: it lets us subtract inherited variation and keep only what is unique to the cancer. Without it, we cannot tell a tumor mutation from a normal one.

Most time-sensitive: how the tumor is handled in the first day or two. Prolonged formalin degrades the sample. If surgery is scheduled, tell us before it happens and we will confirm handling with your team.

A plain-language version you can share with the owner: Preserving a tumor sample →

What the timeline depends on

Your clinic's part — one focused review of the prepared package: 20 minutes.
Sequencing — set by the laboratory, not by us. We confirm the current turnaround with you per case rather than publishing a number we do not control.
Design and documentation — begins when sequencing data arrives and runs on our side.
Anything downstream — manufacture or administration would require the applicable authorizations, and remains your clinical decision.

We would rather tell you the real timeline for your case than publish an average that turns out to be wrong for it.

What your clinic receives

An annotated target-ranking report — the candidate targets found for this patient, ranked, with the evidence behind each. A record of the quality and safety checks that ran — which checks were applied and what they returned, recorded for your review rather than used to decide anything automatically. Sequence files in standard formats — the construct design, exported in the formats a manufacturer works from.

Model names, thresholds and internal formats stay inside the package.

Who does what

Owner
  • Shares the dog's history and records
  • Stays in the loop at every step
Veterinarian
  • Diagnoses and sends samples
  • Reviews and approves the vaccine design 20 min
  • Vaccinates the dog
RosieVaccine
  • A partner laboratory sequences the tumor and normal samples
  • We create the personalized vaccine design and report
  • A partner manufacturer produces the mRNA vaccine

Manufacture and administration depend on the applicable authorizations, which are not yet in place. Every clinical decision is yours.

Evidence and limitations

Human precedent: a phase 3 trial of an individualized mRNA neoantigen therapy plus pembrolizumab met its recurrence-free and distant metastasis-free survival endpoints in resected melanoma (August 2026; no effect size published yet). The randomised phase 2b of the same programme (KEYNOTE-942, n=157) reported HR 0.51 (95% CI 0.294–0.887) for recurrence or death at five years. Precedent for the method in humans — not evidence of benefit in dogs.

Canine: a licensed melanoma DNA vaccine's licensure study (n=58+53, historical controls) vs a later retrospective (n=45) with no PFS/DFI/MST benefit. No canine efficacy data exists for personalized mRNA designs.

PMID 38246194 · 22126691 · 23909996 · reviewed 2026-08-12
Operational questions
Does referring commit my clinic or client to anything?
No. A referral starts an individual technical review. It is not enrolment, it creates no obligation for you or your client, and either side can stop at any point.
Can my client get a vaccine now?
No. No RosieVaccine product is licensed or available. Any administration would require the applicable federal and state authorizations, and would be your clinical decision, not ours.
What does a case cost?
We don't publish pricing, because the sequencing and manufacturing inputs are not settled. We will tell you what is and isn't covered before anything is committed.
Who owns the data and the report?
The clinical record stays yours and your client's. The design report is produced for the case and shared with you; our data handling is described in the privacy policy.

Have a case in mind?

Referring a patient starts an individual review by our science team — it is not enrolment, and no product is available. Replies come from a named scientist.

Refer a Patient →